Send to

Choose Destination

Methods for Antimicrobial Susceptibility Testing for Human Mycoplasmas; Approved Guideline [Internet].


Wayne (PA): Clinical and Laboratory Standards Institute; 2011 Oct. Report No.: M43-A.
CLSI Standards: Guidelines for Health Care Excellence.


Antimicrobial susceptibility testing is indicated for any organism that contributes to an infectious process warranting antimicrobial chemotherapy, if its susceptibility cannot be reliably predicted from knowledge of the organism’s identity. Standardized in vitro antimicrobial susceptibility tests are also needed in order to evaluate new antimicrobials against specific groups of organisms in comparison with existing agents. Acquired resistance to one or more classes of antimicrobial agents has now emerged in the major mycoplasmal and ureaplasmal species that infect humans, hence the need to establish accurate and reproducible methods to measure antimicrobial activities in vitro with these organisms. This document provides guidelines for performance, interpretation, and quality control of in vitro broth microdilution and agar dilution susceptibility tests for several antimicrobial agents suitable for use against Mycoplasma pneumoniae (M. pneumoniae), Mycoplasma hominis (M. hominis), and Ureaplasma species (Ureaplasma spp). Information in this document includes designated reference strains and the expected minimal inhibitory concentration ranges for specific drugs that should be obtained when they are tested. Clinical and Laboratory Standards Institute (CLSI). Methods for Antimicrobial Susceptibility Testing for Human Mycoplasmas; Approved Guideline. CLSI document M43-A (ISBN 1-56238-769-3 [Print]; ISBN 1-56238-770-7 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2011.

Copyright ©2011 Clinical and Laboratory Standards Institute.


    Support Center